Preliminary Final Report
| Stock | Dusk Group Ltd (DSK.ASX) |
|---|---|
| Release Time | 29 Aug 2025, 8:43 a.m. |
| Price Sensitive | Yes |
Dusk Group Ltd reports strong FY25 results
- Statutory total sales up 7.8% to $137.4m
- Statutory EBIT up 19.8% to $9.0m
- Underlying EBIT up 22.9% to $7.7m
- Underlying NPAT up 21.8% to $6.1m
Dusk Group Limited has reported a strong financial performance for the year ended 29 June 2025 (FY25), with increases in revenue, earnings, and profitability. Statutory total sales were up 7.8% to $137.4 million, statutory EBIT increased by 19.8% to $9.0 million, and statutory NPAT grew by 5.5% to $4.4 million. The company's underlying EBIT, which excludes certain one-off costs and adjustments, rose by 22.9% to $7.7 million, while underlying NPAT increased by 21.8% to $6.1 million. The board and management team are pleased with the business's return to growth, attributing it to the company's vertically integrated model, successful dusk Rewards program, and focus on product innovation and international expansion. During the year, dusk opened two new stores in Australia, bringing the total to 145 stores. The online channel also performed strongly, with sales increasing by 50.1% to $10.8 million. The company continues to explore opportunities for international expansion, with a trial in New Zealand ongoing. Looking ahead, dusk remains focused on its key strategic initiatives, including further product innovation, omni-channel growth, and disciplined cost management, which the board believes will drive long-term shareholder value.
Dusk Group Ltd expects to maintain its strong financial performance in FY26, with continued growth in revenue, EBIT, and NPAT. The company plans to rejuvenate its largest core product range in the first half of FY26.
Dusk Group Ltd remains focused on its key strategic initiatives, including further product innovation, omni-channel growth, and disciplined cost management, which the board believes will drive long-term shareholder value. The company is also exploring opportunities for international expansion, with a trial in New Zealand ongoing.